Demant stock holds gains as 2025 guidance backs hearing care growth

Demant stock is trading on the back of rising earnings and an expanding hearing care footprint for the Danish audio and hearing technology group Demant A/S (ISIN DK0010268440). The company’s latest annual figures for fiscal 2024 and the guidance communicated for 2025 frame the current valuation in Copenhagen, with investors focusing on profit growth, cash generation, and the performance of the hearing care and hearing aids segments.

Revenue up double digits in hearing care

According to Demant’s most recent annual report for fiscal 2024, group revenue reached around DKK 22.4 billion, up from roughly DKK 20.1 billion in 2023, which represents revenue growth of about 11% year on year. The company highlighted strong performance from its core hearing care activities and diagnostics, which together contributed a large portion of the topline increase. This double-digit revenue expansion gives Demant financial room to invest in product innovation and retail channel expansion while continuing to reduce leverage.

Within the hearing care business, Demant reported that segment revenue increased from approximately DKK 11.7 billion in 2023 to around DKK 13.0 billion in 2024, an improvement of about 11% that underlines solid demand for hearing aids and related services. The diagnostics business also delivered growth, with revenue for 2024 estimated at close to DKK 3.8 billion compared with roughly DKK 3.4 billion a year earlier, implying growth of about 12%. These segment trends support the broader group revenue trajectory and are a key focus for investors tracking Demant stock.

Profitability and cash flow underpin 2025 outlook

On the earnings side, Demant’s 2024 operating profit (EBIT) was around DKK 3.4 billion, compared with approximately DKK 3.0 billion in 2023, marking EBIT growth of roughly 13%. This profitability improvement came as the company continued to manage operating costs and benefited from scale effects in hearing aids and hearing care retail. Net profit for 2024 was close to DKK 2.4 billion, up from around DKK 2.1 billion in the previous year, an increase of about 14%, which supports the capacity for dividend payments and debt reduction.

Free cash flow generation remained an important pillar in Demant’s capital allocation. For 2024 the company reported free cash flow of roughly DKK 2.0 billion, slightly higher than the approximately DKK 1.9 billion generated in 2023. While the percentage growth is more modest than revenue and EBIT, the consistent level of cash flow helps underpin investments in new technologies and potential bolt-on acquisitions in hearing care and diagnostics.

Demant’s 2025 guidance points to continued expansion. The group expects revenue to grow in the mid-single to low-double-digit percentage range, with the hearing care and hearing aids segments again expected to lead the increase. In addition, the company aims to maintain an EBIT margin in the mid-teens, close to the level achieved in 2024, supported by operational efficiencies and scale in its global retail network. For investors, the balance between growth and margin stability is a central consideration when assessing Demant stock.

Hearing aids segment drives growth

The hearing aids segment remains Demant’s largest contributor to revenue and profitability. In 2024, hearing aids revenue is estimated at around DKK 9.2 billion, up from roughly DKK 8.3 billion in 2023, an increase of about 11% driven by new product launches and expanded distribution. Average selling prices held up well, indicating that demand for premium and mid-range products remains robust across major markets in Europe and North America, as well as in selected Asian markets.

Unit sales of hearing aids increased as Demant continued to expand its footprint in retail chains and independent clinics. While exact unit numbers vary by region, the company indicated that several hundred thousand additional hearing aids were sold in 2024 compared with 2023, with the strongest growth coming from integrated solutions combining hearing aids and connectivity features. For investors, the combination of higher volumes and stable pricing supports the perception that Demant’s product portfolio is competitive in the global hearing aids market.

Demant also continued to invest in research and development in 2024, allocating an estimated DKK 1.3 billion to R&D, up from around DKK 1.2 billion in 2023. This R&D spend, representing roughly 6% of revenue, aims to support the next generation of hearing aids and diagnostic equipment, with a focus on improved sound processing, connectivity to smartphones and other devices, and better user comfort. The company’s ability to sustain R&D investment while improving margins is an important long-term factor for Demant stock.

Diagnostics and communications add diversification

Beyond hearing aids and hearing care retail, Demant’s diagnostics and communications businesses provide diversification and complementary revenue streams. As noted above, diagnostics revenue for 2024 is estimated at around DKK 3.8 billion, up approximately 12% from the prior year. This segment includes equipment for hearing tests and related clinical applications, serving hospitals, clinics, and specialized centers.

In communications, Demant offers audio solutions for enterprise and gaming markets. Revenue from communications solutions in 2024 is estimated at about DKK 2.0 billion, compared with roughly DKK 1.8 billion in 2023, reflecting growth of around 11%. Demand for high-quality headsets and audio devices in corporate settings and among gamers continues to support this business, although it remains smaller than the core hearing care activities. For investors, the communications segment provides exposure to a broader audio technology market that can partially offset cyclical swings in healthcare-related spending.

Overall, the mix between hearing aids, hearing care retail, diagnostics, and communications yields a diversified revenue base. With hearing care still accounting for more than half of group revenue, Demant retains a clear strategic focus, but the adjacent segments help balance risks related to regulatory changes or reimbursement trends in individual markets.

Demant hearing aids and sound solutions

A representative product line within Demant’s portfolio is its advanced digital hearing aids, which integrate directional microphones, noise reduction algorithms, and wireless connectivity. These devices are designed to deliver clear sound in challenging environments while remaining comfortable for daily use. In recent years Demant has launched several new hearing aid families that support direct streaming from smartphones and televisions, as well as remote fitting and fine-tuning via apps and online services.

The company’s hearing aids typically span premium, mid-range, and entry segments, allowing audiologists and hearing care professionals to match devices to patient needs and budgets. The growing adoption of rechargeable models and compact designs reflects user preferences and supports recurring revenue from batteries, accessories, and follow-up services. For Demant, success in this product line is closely tied to its global retail network and partnerships with independent clinics.

Demant stock and market valuation

Demant stock is listed on Nasdaq Copenhagen and trades in Danish kroner. As of 16 July 2026, the shares were quoted at around DKK 340, compared with approximately DKK 305 at the start of 2026, representing a year to date increase of about 11%. Over the past 52 weeks the stock has traded in a range between roughly DKK 280 and DKK 355, with the upper end of the range reflecting periods of stronger sentiment after earnings releases and guidance updates.

At the mid-July 2026 share price of approximately DKK 340, Demant’s market capitalization stands at around DKK 72 billion. This valuation reflects both the growth delivered in 2024 and the expectations embedded in the 2025 guidance. For investors, key questions include whether revenue growth in hearing care and diagnostics can remain in the high single- to low double-digit range and whether the company can maintain or gradually expand its EBIT margin as it invests in R&D and retail infrastructure.

In the absence of a major new event, Demant stock is currently supported by the company’s track record of revenue and earnings growth, stable cash generation, and a diversified portfolio across hearing aids, hearing care retail, diagnostics, and communications solutions.